spacer
home > pmps > autumn 2009 > skin deep
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Skin Deep

 

At the current time, when companies from all sectors, including those from the pharmaceutical industry, are experiencing the impact of recession, it is critical that they make optimal use of available resources. In a recent presentation at the annual meeting of the Controlled Release Society, it was proposed that the way out of this situation is for companies to invest wisely in the areas driven by the importance of therapy, molecule and use of efficient novel techniques (1). Some of the areas demanding attention and investment include oncology, immunology, endocrinology, central nervous system, cardiology and diabetes. Drug molecules for the treatment of most of these indications happen to be therapeutic proteins, macromolecules and biopharmaceuticals. Furthermore, investment in the use of novel and efficient drug delivery techniques to enable the delivery of these molecules is needed. Among the possible delivery routes, topical and transdermal drug delivery systems seem to be a promising route for the delivery of biopharmaceuticals.

Transdermal is the third most common route of drug delivery, behind oral and parenteral routes. It offers several advantages over other routes: for example, it bypasses hepatic metabolism (first pass effect), provides protection from harsh GIT conditions (especially beneficial for proteins), reduces systemic drug exposure, simulates intravenous infusion, allows less frequent administration for drugs with short half life, provides ease of termination of therapy in case of overdose, offers high patient compliance and acceptability, reduced drug usage and improved use of resources. As is true with any other technique, transdermal drug delivery systems (TDDS) have some limitations as well. Due to the excellent barrier properties of the skin, only moderately lipophilic (log P between 1 and 3.5), highly potent (dose ~10mg per day from a 10cm2 patch) and small drug molecules (MW < 500Da) can diffuse passively for systemic or local action. As a result of these limitations, most of the transdermal products in the market today are for small, moderately lipophilic molecules. These include the scopolamine patch (TDDS on market indicated for motion sickness), nicotine patch (smoking cessation), fentanyl patch (postoperative pain management) and others. Ongoing research is expected to expand the range and type of drug molecules that can be delivered via this route. A number of enhancement techniques have been tried to achieve this goal. These include use of chemical enhancers, electrical and ultrasound energy assisted enhancement techniques such as iontophoresis and sonophoresis, respectively (second generation), and the most recent (third generation) technology is microporation (mechanical, thermal, laser and radiofrequency ablation) (2). This article will discuss second and third generation enhancement techniques with a primary focus on their practical aspects, major challenges in their development, and progress towards commercialisation for the delivery of biopharmaceuticals. These biopharmaceuticals do not normally diffuse passively through the skin as they are water soluble molecules. Furthermore, many are macromolecules, which present further challenges for transdermal delivery.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Vishal Sachdeva completed his Bachelors of Pharmacy from Delhi University, India. He is currently pursuing his PhD in Transdermal Drug Delivery under Dr Ajay K Banga at Mercer University College of Pharmacy and Health Sciences, Atlanta, US, and is in the third year of the programme. He has been working in the areas of conventional patch technology, iontophoresis for enhanced delivery of small drug molecules and microneedles assisted delivery of macromolecules. He has been an active student member of the American Association of Pharmaceutical Scientists (AAPS), Controlled Release Society (CRS) and Modified Release Focus Group (MRFG) in AAPS. He has presented his research work as posters and podiums in various conferences of AAPS, GRASP and CRS. As a student member in the steering team of MRFG, he has been writing articles for the newsletter on topics related to different areas of drug delivery.

Dr Ajay K Banga is Professor and Chair in the Department of Pharmaceutical Sciences at the College of Pharmacy and Health Sciences, Mercer University, Atlanta, US. His research expertise is in non-traditional approaches to transdermal drug delivery, especially for water-soluble drugs including small conventional molecules and macromolecules. Ajay has a PhD in Pharmaceutics from Rutgers University, US. He currently serves on the Editorial Board of seven journals and has served as Editor-in-Chief for a drug delivery journal. He has written two books in the areas of delivery of proteins and transdermal delivery. He has served on over 30 thesis/dissertation advisory committees and as a referee for over 28 journals. He is a Fellow of the American Association of Pharmaceutical Scientists.

spacer
Vishal Sachdeva
spacer
spacer
spacer
Ajay K Banga
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arcis Biotechnology appointments Professor Steve Howell as Non-Executive Chairman

Daresbury, UK, 24 July 2019: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has appointed Professor Steve Howell as Non-Executive Chairman of its Board of Directors. Steve takes over the position from Paul Foulger, who was serving as Chairman on an interim basis on behalf of the Board.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement